Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06119217 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients
A Phase 2 study of Pancreatic Cancer, sponsored by Trishula Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 194
- Enrollment target
- 20
- Study locations
NCT06119217: Active Phase 2 study of Pancreatic Cancer, sponsored by Trishula Therapeutics.
NCT06119217 is a Phase 2 study of Pancreatic Cancer that is active but no longer recruiting, run by Trishula Therapeutics. The registered enrollment target is 194 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (51% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06119217, a Phase 2 study of Pancreatic Cancer, is active but no longer recruiting, sponsored by Trishula Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 194 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2, multicenter, open-label, 3-arm, randomized, parallel group study to evaluate the efficacy and safety of TTX-030 with or without budigalimab in combination with chemotherapy (gemcitabine + nab-paclitaxel) in subjects with metastatic PDAC who did not have prior treatment for metastatic disease and are eligible to receive gemcitabine and nab-paclitaxel chemotherapy as SOC.
Primary Outcome
PFS is defined as the time from randomization until first documentation of progression or death from any cause, whichever occurs first
Conditions Studied
Interventions
- COMBINATION_PRODUCT TTX-030, nab-paclitaxel and gemcitabine
- COMBINATION_PRODUCT TTX-030, budigalimab, nab-paclitaxel and gemcitabine
- COMBINATION_PRODUCT Nab-Paclitaxel and gemcitabine
Study Locations (20)
California
- Investigative Site - Bakersfield
- Investigative Site - Fullerton
- Investigative Site - Los Angeles
Florida
- Investigative Site - St. Petersburg
- Investigative Site - West Palm Beach
Oregon
- Investigative Site - Eugene
- Investigative Site - Portland
Arizona
- Investigative Site - Tucson
Arkansas
- Investigative SIte - Hot Springs
Colorado
- Investigative Site - Denver
Georgia
- Investigative Site - Atlanta
Kansas
- Investigative Site - Wichita
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 194 participants |
| Start Date | 2024-03-25 |
| Est. Completion | 2027-06 |
| Phase | Phase 2 |
What the registry record for NCT06119217 still lists
NCT06119217 is an interventional study that assigns participants to a tested intervention. The registered 194 participants enrollment target is mid-sized for trials with a published cap, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (51% lower).
The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 3 interventions - of which TTX-030, nab-paclitaxel and gemcitabine is the first listed.
NCT06119217 names 20 study sites across 16 states, led by California, Florida, Oregon.
Frequently Asked Questions
What is clinical trial NCT06119217 about?
NCT06119217 is a clinical study titled "Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients". This is a Phase 2, multicenter, open-label, 3-arm, randomized, parallel group study to evaluate the efficacy and safety of TTX-030 with or without budigalimab in combination with chemotherapy (gemcitabine + nab-paclitaxel) in subjects with metastatic PDAC who did not have prior treatment for metasta...
What is the current status of trial NCT06119217?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 194 participants. The study started on 2024-03-25. Estimated completion is 2027-06.
What conditions does trial NCT06119217 study?
This clinical trial studies the following conditions: Pancreatic Cancer.
What interventions are being tested in trial NCT06119217?
The interventions under investigation include: TTX-030, nab-paclitaxel and gemcitabine (COMBINATION_PRODUCT), TTX-030, budigalimab, nab-paclitaxel and gemcitabine (COMBINATION_PRODUCT), Nab-Paclitaxel and gemcitabine (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06119217?
This trial is sponsored by Trishula Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06119217 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06119217's enrollment target sits among peer trials
194 68th of 278 higher than 211 of 278 other Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial
RECRUITING · Phase 2
-
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
RECRUITING · Phase 2
-
Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03593759 · 194 participants · Phase 3
Cardiac Sarcoidosis Randomized Trial
- NCT05053152 · 194 participants · Phase 2
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
- NCT05156112 · 194 participants · NA
OSA PAP Treatment for Veterans With SUD and PTSD on Residential Treatment Unit
- NCT05351424 · 194 participants · NA
AVI Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment Study in Rad Onc
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI